Pharmasyntez and Pharmasyntez-Tyumen, which are parts of the Pharmasyntez Group, have successfully passed a GMP inspection by the Libyan Ministry of Health.
In December 2024, Pharmasyntez, and Pharmasyntez-Tyumen, successfully underwent an inspection by the Libyan Ministry of Health to ensure compliance with the Good Manufacturing Practice (GMP) standards. This inspection represents a crucial step in guaranteeing the quality and safety of the produced medicinal products.
On March 12, 2025, the companies received the GMP certificate from Libya, paving the way for the supply of high-quality medications to the Libyan market. This achievement will greatly increase Pharmasyntez's prospects on the international stage in addition to boosting consumer confidence in the company's products.
"The Pharmasyntez Group is taking confident steps to expand its presence on the international stage," commented Nikita Punia, Executive Director of the Pharmasyntez Group. “The provision of pharmaceuticals from Russian manufacturing plants in Irkutsk and Tyumen has been formally authorized by the Libyan Ministry of Health. In the near future, regular deliveries of high-quality medicines will begin, marking an important step in providing Libyan patients with accessible and effective treatments. This move underscores the growing authority of Russian manufacturers in the global market and their ability to compete with leading international pharmaceutical brands."
As the demand for high-quality medicines in Libya continues to grow, the GMP certification will be a key factor in successfully competing in the local market and strengthening Pharmasyntez's position in the region.
The Pharmasyntez Group is one of the top Russian biopharmaceutical companies, operating across various segments of the healthcare industry, including research, development, production, and distribution of socially significant medicines, innovative therapies, and active pharmaceutical ingredients.
The Pharmasyntez-Tyumen plant is the only facility in the country and the largest in Europe specializing in the production of hormonal medications.